GeoVax Labs, Inc. has begun engaging with global health and preparedness organizations to explore potential future procurement of its GEO-MVA vaccine candidate for mpox and smallpox preparedness programs. The company is soliciting interest from international organizations that influence or directly procure vaccines for national preparedness stockpiles and international outbreak response programs.
This outreach reflects growing global recognition of the need to diversify supply of Modified Vaccinia Ankara vaccines used for protection against mpox and smallpox. Currently, global supply of MVA vaccines is concentrated in a single commercial manufacturer, creating potential vulnerabilities in global health security. Global preparedness programs for smallpox and mpox vaccines represent a potential multi-billion-dollar procurement market supported by national stockpiles, military preparedness programs, and international health organizations.
GeoVax believes that initiating engagement with procurement and preparedness organizations represents an important transition from development toward commercialization planning. This reflects growing confidence in the GEO-MVA program and the potential for the vaccine to contribute to global preparedness stockpiles following successful completion of the planned Phase 3 study, scheduled to initiate in the second half of 2026.
The GEO-MVA program has progressed through extensive regulatory dialogue with the European Medicines Agency, culminating in scientific advice supporting an expedited development pathway based on a single immunobridging trial to the licensed MVA vaccine. David Dodd, Chairman and Chief Executive Officer of GeoVax, stated that the EMA's guidance validates both the scientific foundation of GEO-MVA and the growing recognition that expanding global MVA vaccine supply is an important public health priority.
The discussions initiated by GeoVax occur amid growing policy dialogue regarding the strategic importance of expanding global MVA vaccine manufacturing capacity. Recent mpox outbreaks have reinforced the understanding that mpox is not a single episodic event, but rather an evolving infectious disease threat with potential for continued geographic expansion and recurrence. As a result, governments and international health organizations are increasingly emphasizing the need for manufacturing diversification and supply redundancy for vaccines used in outbreak response and biodefense preparedness.
In the United States, policymakers and defense stakeholders have increasingly recognized that no domestic manufacturing capability currently exists for MVA vaccines, a gap with implications for both civilian preparedness and military readiness. Dodd noted that establishing additional MVA manufacturing capability is increasingly viewed as an important component of global preparedness, with growing interest from public health organizations, governments, and defense stakeholders who recognize the strategic importance of supply diversification.
GEO-MVA is GeoVax's candidate vaccine for protection against mpox and smallpox based on the Modified Vaccinia Ankara platform. Pending successful completion of the planned immunobridging trial, GEO-MVA could represent an important additional source of MVA vaccine supply for global preparedness, outbreak response, and biodefense programs. For more information about the company, visit https://www.geovax.com.
